Biological Psychiatry Global Open Science

GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction

By Joshua Reitz, Daniel B. Rosoff, Pál Pacher, Falk W. Lohoff

ReviewInterventions

The paper

Joshua Reitz, Daniel B. Rosoff, Pál Pacher, Falk W. Lohoff

National Institutes of Health

Biological Psychiatry Global Open Science, 23 Jul 2026

doi.org/10.1016/j.bpsgos.2026.100793 PubMed 42741173

Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Alzheimer's & Dementia7 Oct 2026
Brain receptor gene activity linked to lower Alzheimer’s risk